Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Accelerating global innovation to address antibacterial resistance: introducing CARB-X

Nature Reviews Drug Discovery volume 15, pages 589–590 (2016)Cite this article

Subjects

Abstract

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations http://amr-review.org (2016).

  2. Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. Lancet Infect. Dis. 13, 1057–1098 (2013).

    Article  Google Scholar 

  3. Rex, J. H. & Outterson, K. Antibiotic reimbursement in a sales-delinked model: context and a benchmark-based global approach. Lancet Infect. Dis. 16, 500–505 (2016).

    Article  Google Scholar 

  4. Outterson, K. New business models for sustainable antibiotics. Chatham House http://www.chathamhouse.org/publications/papers/view/197446 (2014).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston University School of Law, Boston, 02215, Massachusetts, USA

    Kevin Outterson

  2. Chatham House, London, SW1Y 4LE, UK

    Kevin Outterson

  3. AstraZeneca Pharmaceuticals, Waltham, 02451, Massachusetts, USA

    John H. Rex

  4. University of Texas Medical School–Houston, Houston, 77225, Texas, USA

    John H. Rex

  5. Wellcome Trust, London, NW1 2BE, UK

    Tim Jinks

  6. AMR Centre, Alderley Park, SK10 4TG, Manchester, UK

    Peter Jackson

  7. Mass Bio, Cambridge, 02139, Massachusetts, USA

    John Hallinan

  8. California Life Sciences Institute, South San Francisco, 94080, California, USA

    Steve Karp

  9. Broad Institute, Cambridge, 02142, Massachusetts, USA

    Deborah T. Hung

  10. Harvard Medical School, Boston, 02215, Massachusetts, USA

    Deborah T. Hung

  11. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    Deborah T. Hung

  12. National Institute of Allergy and Infectious Diseases, Bethesda, 20892, Maryland, USA

    Francois Franceschi, Dennis M. Dixon, Michael G. Kurilla & Rosemarie Aurigemma

  13. Biomedical Advanced Research and Development Authority, 20201, Washington, DC, USA

    Tyler Merkeley, Christopher Houchens & Joseph Larsen

Authors
  1. Kevin Outterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John H. Rex
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tim Jinks
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John Hallinan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steve Karp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Deborah T. Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francois Franceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tyler Merkeley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christopher Houchens
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dennis M. Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michael G. Kurilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rosemarie Aurigemma
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Joseph Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin Outterson.

Ethics declarations

Competing interests

J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals, non-executive board member, senior advisor and shareholder of F2G Pharmaceuticals; non-executive board member of Adenium Biotech ApS; Expert-in-residence, Wellcome Trust; and operating partner and consultant, Advent Life Sciences. P.J. is executive director of AMR Centre Ltd; non-executive director of Redx Pharma Plc; non-executive director of Yprotech Ltd; non-executive director of Biovictrix Therapeutics Ltd; and owner and director of Intelia Consulting.

Related links

Related links

FURTHER INFORMATION

CARB-X

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Outterson, K., Rex, J., Jinks, T. et al. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 15, 589–590 (2016). https://doi.org/10.1038/nrd.2016.155

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.155

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research